📌 Key Takeaways
- Topic: What Is Amorphous Silica? Types, Safety Profile and Industrial Uses
- Keywords: fumed silica 200 m2/g
- Published: 2026-11-20 02:51:57
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica Mesh Size Chart: Mesh to Micron Conversion and How to Choose
- Wollastonite vs Silica: Filler Performance and Applications Compared
- Aerosil Alternative: Equivalent Fumed Silica Grades and How to Switch
- 100. Karaman D.Ṣ., Patrignani G., Rosqvist E., Smått J.-H., Orłowska A., Mustafa R., Preis M., Rosenholm J.M. Mesoporous silica nanoparticles facilitating the dissolution of poorly soluble drugs in orodispersible films. Eur. J. Pharm. Sci. 2018;122:152-159. doi: 10.1016/j.ejps.2018.06.027. [ DOI ] [ PubMed ] [ Google Scholar ]
- Silica for Tires: How It Reduces Rolling Resistance and Improves Wet Grip
- 7. Vallet-Regi M., Rámila A., Del Real R.P., Pérez-Pariente J. A new property of MCM-41: Drug delivery system. Chem. Mater. 2001;13:308-311. doi: 10.1021/cm0011559. [ DOI ] [ Google Scholar ]
- Monocrystalline Silicon vs Silica: How Silicon Wafers Are Made from Quartz
- Project No. TKP2021-EGA-32 was implemented with support provided by the Ministry of Culture and Innovation of Hungary through the National Research, Development, and Innovation Fund, financed under the TKP2021-EGA funding scheme.
Silica TDS: What a Technical Data Sheet Includes and How to Compare Grades
What is silica (SiO₂)?
nano silica supplier 31. Ismail A., Sial N., Rehman R., Abid S., Ismail M.S. Survival, expansion, behavior, hematology and serum biochemistry of mice under different concentrations of orally administered amorphous silica nanoparticle. Toxicol. Rep. 2023;10:659-668. doi: 10.1016/j.toxrep.2023.05.006. [ DOI ] [ PMC free piece ] [ PubMed ] [ Google Scholar ]
What is the difference between fumed silica and precipitated silica?
spherical alumina The skin is our largest organ, which consists of three layers: the epidermis, dermis, and hypodermis. Owing to its big surface zone, it also serves as an essential gateway for drug administration [ 25 ], which is fitting for both local (dermal) or systemic (transdermal) therapy [ 25, 56 ]. In spite of the popularity of this administration route, it is a challenge to get the API into deeper layers of the skin. The outermost layer of the epidermis, the stratum corneum, is the biggest hurdle to molecular penetration [ 25, 56 ]. However, the molecules must be absorbed through the capillaries of the dermis to achieve a systemic impact, which can be facilitated employing nanocarriers [ 56 ]. In addition, sweat glands or hair follicles can be effective alternative routes for the molecules to enter the deeper layers of the skin [ 25, 56 ]. In summary, it can be called as the transappendageal route. Among physicochemical properties, particle size is one of the most vital factors influencing absorption. Particles in the range between 200 and 300 nm are suitable for local treatment of the skin in diseases such as atopic dermatitis [ 25 ] since particles larger than 75 nm do not pass through the stratum corneum [ 25 ]. Smaller particles (approximately 50 nm) are suitable for systemic treatment [ 25 ], and on the whole, it can be said that nanoparticles with a diameter smaller than 25 nm can penetrate the skin most effectively, so they can be used for transdermal drug administration with an appropriate formulation [ 56 ]. By controlling the size of the nanocarrier, they penetrate to different depths in the skin. From the element of surface characteristics, cationic amino-functionalized MSNs show more efficient penetration into deeper layers of the skin than the particles with anionic surfaces of the same size [ 25 ]. The use of MSNs as a drug carrier may improve aqueous solubility, stability, and skin penetration of the drug [ 61 ]. In a research, gels containing MSN were prepared by employing distilled water to form the base, adding the gelling agent (Poloxamer 407), and adding HPMC to enhance the viscosity [ 83 ]. In another publication, MSN containing oleogels were prepared with sunflower oil and the addition of colloidal silicon dioxide as a gelling agent [ 61 ]. According to in vitro experiments, the gel matrix also affected the drug release kinetics [ 61, 83 ]. Slower drug release was observed in the case of gels containing loaded MSNs, compared to the free carriers, and the outcomes demonstrated close to zero-order release kinetics [ 61 ]. According to in vitro biocompatibility studies, this gel complex did not show any evidence of cytotoxicity on dermal fibroblast cells. Moreover, according to in vivo dermal safety studies, it has been proven that this preparation does not cause skin irritation during application, and so this formulation can be considered a safe product [ 61 ].
What drives silica raw material prices?
Sibelco quartz Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.